Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin

Purpose We aimed to identify potential clinical parameters that can be easily obtained by a pre-treatment clinicopathological evaluation and whole blood test to estimate the development of oxaliplatin-induced peripheral neuropathy (OIPN). Methods This study was conducted retrospectively. For the FOLFOX regimen, patients received oxaliplatin, 85 mg/m 2 , every 2 weeks for 12 courses, and with the XELOX regimen, oxaliplatin was 130 mg/m 2 , every 3 weeks for 6–8 courses. The incidence and degree of neuropathy (NCI-CTCAE v.3) were recorded. Results A total of 186 patients were included in the study. There were 108 (58%) patients in the grade 0–1 (G0–G1) neuropathy group (mean age 50.5 ± 11.5; 63% men), and 78 (42%) patients in the grade 2–3 (G2–G3) neuropathy group (mean age 58.0 ± 10.8; 46.2% men). The relationship between G2–G3 OIPN development and age ( p